研究单位：[1]Pfizer[2]First Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China,650032[3]Beijing Friendship Hospital,Capital Medical University Beijing,Beijing,China,100050[4]Dermatology Hospital of Southern Medical University Guangzhou,Guangdong,China,510091[5]The Second Affiliated Hospital of Guangzhou Medical University Guangzhou,Guangdong,China,510260[6]The First Affiliated Hospital of Shantou University Medical College Shantou,Guangdong,China,515041[7]Shenzhen Children's Hospital Shenzhen,Guangdong,China,518026[8]Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology Wuhan,Hubei,China,430030[9]The Second Xiangya Hospital of Central South University Changsha,Hunan,China,410011[10]The First hospital of Jilin University Changchun,Jilin,China,13002
研究目的：
This study is a phase 3, randomized, double blind and vehicle study to evaluate the efficacy and safety of Crisaborole ointment, 2% in Chinese and Japanese subjects with mild to moderate atopic dermatitis involving at least 5% treatable BSA. Eligible subjects will be randomized in a 2:1 ratio to one of 2 treatment groups (Crisaborole BID, Vehicle BID, respectively).
